The company’s quarterly performance was buoyed by significant volume growth in the United States, which climbed 60%, and a 70% surge in its Liquid Biopsy business. Ross Muken, stepping into the CEO role, emphasized that the firm is leveraging its AI-native platform to convert scientific credibility into sustainable, profitable growth. To support these objectives, SOPHiA GENETICS bolstered its balance sheet with a $57.5 million public offering, leaving it with $107.7 million in cash reserves at the end of June.

Strategic expansion remains a priority, highlighted by the signing of two companion diagnostic programs with AstraZeneca—a first for the organization. Additionally, the company is refining its portfolio through a joint venture with Memorial Sloan Kettering Cancer Center, aimed at developing an 'AI Lab of the Future.' Despite a net loss of $22.4 million, the company improved its adjusted EBITDA loss by 27% compared to the prior year. Management has raised its full-year 2026 revenue guidance to a range of $94 million to $96 million, reaffirming its commitment to reaching positive adjusted EBITDA by the second half of 2027.